Keros Therapeutics

KEROS THERAPEUTICS INC

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

benzinga_deal_dispatch2

Asset Sales

CPRI

CSSPF

KROS

LCID

NKLAQ

RVLCF

Things are hog wild at Harley-Davidson; Plus, Impresoft, Keros Therapeutics and Rivalry Corp. are all itching for a deal.

Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada&#39;s Versace Purchase Garners A Fashionable Price

Munich,,Bavaria,,Germany,-,March,31,2023:,Keros,Therapeutics,Leads

Biotech

News

Health Care

Movers

Trading Ideas

General

Keros Therapeutics launches strategic review and adopts rights plan after investor activity signals potential changes in company control.

Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan

Crude Oil and Petroleum Trade in the Crosshairs

Equities

Eurozone

Commodities

Intraday Update

Markets

KTTA

MRIN

RSLS

VERO

Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump

Keros Therapeutics Inc

KROSAKI HARIMA CORP by KROSAKI HARIMA CORP.

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS

Earnings

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

Keros Therapeutics Announces Review of Strategic Alternatives

Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders

Keros Reinforces Commitment to Maximizing Stockholder Value

Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference

ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth

Akebia Therapeutics

AnaptysBio

ArriVent BioPharma

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Cogent Biosciences

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Immatics

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Inventiva S.A. - American Depository Shares

Inventiva

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Kura Oncology

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Replimune Group

Regulus Therapeutics

Relay Therapeutics

Sionna Therapeutics

Stoke Therapeutics

Savara

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Tyra Biosciences

Upstream Bio

Valneva

Vir Biotechnology

Xencor

Scotiabank

HC Wainwright & Co.

Truist Securities

Wedbush

Wells Fargo

Comments

Keros Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell